Alteogen Shares Fall Against Rising Major Indices... "Now Performance Matters More Than Deals"
Alteogen (196170), the top company by market capitalization on the KOSDAQ, is falling alone while both major indices rise in tandem. As of 11:29 a.m. on the 8th, Alteogen is trading at 278,000 won, down 8,000 won (2.80%) from the previous trading day. At the same time, the KOSPI index stands at 7,1

Alteogen (196170), the top company by market capitalization on the KOSDAQ, is falling alone while both major indices rise in tandem.
As of 11:29 a.m. on the 8th, Alteogen is trading at 278,000 won, down 8,000 won (2.80%) from the previous trading day. At the same time, the KOSPI index stands at 7,132.07, up 136.68 points (1.95%) from the previous session, while the KOSDAQ index is up 7.04 points (0.85%) at 829.23. With both indices rising together, only Alteogen is moving against the market, dipping below the 280,000-won level. Still, the KOSDAQ index is maintaining its upward trend despite the weakness of its leading stock.
Amid this, Hana Securities maintained its 'Buy' investment opinion and target price of 450,000 won for Alteogen on the 7th. The firm analyzed that attention should now be paid to the performance resulting from contracts and the timing of cash inflows, rather than whether additional deals will be struck.
On the 2nd, Alteogen signed a technology transfer contract with Novartis worth 3.233 billion dollars, or about 4.4165 trillion won, including upfront payments and milestones. Royalties are separate.
In its report, Hana Securities estimated that, considering the recent contract size, this deal was likely structured around about 10 to 11 products. As many of the products are likely clinical-stage pipeline assets, the firm said cash inflow speed and development risks should be examined, but future events such as option exercises and clinical progress could become mid- to long-term stock price variables.
It also predicted that since Novartis holds various forms of late-clinical assets, including antibodies, antibody-drug conjugates (ADCs), and antibody-oligonucleotide conjugates (AOCs), at least one option is likely to be exercised each year. It further suggested that this type of multi-candidate bundled contract approach could be repeated in deals with other global pharmaceutical companies.
In terms of performance, the firm expects revenue growth to continue through the fourth quarter, with upfront payments from two technology transfers in the third quarter of this year, Qlex sales milestones, and development milestones from existing partnerships scheduled. However, these figures represent the securities firm's forecasts and estimates.
Attention is focused on whether Alteogen, which is showing weakness apart from the broader market rally, can narrow its losses and recover the 280,000-won level in the afternoon session.
[※ This article is for investment reference purposes only, and investment decisions and responsibilities lie with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



